Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed strong safety and efficacy, with plans for a phase 2 trial in 2025.

The same mechanisms involved in COVID-related cardiovascular events are responsible for COVID-related myocarditis.

VirusHB-Chip offers groundbreaking sensitivity in detecting SARS-CoV-2 in plasma, saliva, and stool, transforming COVID-19 diagnostics and treatment strategies.

During the COVID-19 pandemic, health worker Maria Tereza Malheiros Sapienza's curiosity was aroused by her immunity to ...

Learn more about whether Ionis Pharmaceuticals, Inc. or PTC Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Talimogene laherparepvec (T-VEC) demonstrates efficacy in cutaneous BCC, enhancing resectability and altering immune cell ...

VMX 2025 wrapped up last evening setting a bold new standard for innovation, education and leadership in veterinary medicine. VMX 2025 offered more than 1,300 hours of ...

"This type of gene editing should also allow for the treatment of diseases whose origin is not genetic or whose origin cannot ...

Amid this shift, the providers and enablers of healthcare efficiency are well-positioned to reward investors. With an aging ...

Ethris GmbH, a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced promising topline data from the completed Phase 1 clinical trial of its lead mRNA ...